Status:

UNKNOWN

Effect of Dietary Intervention on Gut Microbiome in Hong Kong Obese Population

Lead Sponsor:

The Hong Kong Polytechnic University

Collaborating Sponsors:

Prenetics Limited

Conditions:

Overweight

Eligibility:

All Genders

30-60 years

Phase:

NA

Brief Summary

Modern way of life characterized by decreased physical activity and poor dietary habits seems to be an important trigger for the onset of metabolic disorders. Accumulating evidence indicates that the ...

Detailed Description

1. Purpose of the Study Modern way of life characterized by decreased physical activity and poor dietary habits seems to be an important trigger for the onset of metabolic disorders. Accumulating evid...

Eligibility Criteria

Inclusion

  • With BMI \>23kg/m2 Asian subjects, aged 30-60 years old

Exclusion

  • Chronic, clinically significant (unresolved, requiring on-going medical management or medication) pulmonary, cardiovascular (e.g. heart disease, high blood pressure etc.), gastrointestinal, hepatic or renal functional abnormality, and metabolic syndrome as determined by medical history or physical examination.
  • History of active uncontrolled gastrointestinal disorders or diseases including: inflammatory bowel disease (IBD) including ulcerative colitis (mild-moderate-severe), Crohn's disease (mild-moderate-severe), or indeterminate colitis; irritable bowel syndrome (IBW) (moderate-severe); persistent, infectious gastroenteritis, colitis or gastritis, persistent or chronic diarrhea of unknown etiology, Clostridium difficile infection (recurrent) or Helicobacter pylori infection (untreated); chronic constipation
  • Major surgery of the GI tract, with the exception of cholecystectomy and appendectomy, in the past five years. Any major bowel resection at any time.
  • Use of any of the following drugs within the 1 months sampling: systemic antibiotics, (intravenous, intramuscular, or oral); oral, intravenous, intramuscular, nasal or inhaled corticosteroids; cytokines; methotrexate or immunosuppressive cytotoxic agents; large doses of commercial probiotics consumed (greater than or equal to 108 cfu or organisms per day) - includes tablets, capsules, lozenges, chewing gum or powders in which probiotic is a primary component. Ordinary dietary components such as fermented beverages/milks, yogurts, foods do not apply.

Key Trial Info

Start Date :

November 2 2017

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 31 2018

Estimated Enrollment :

48 Patients enrolled

Trial Details

Trial ID

NCT03343561

Start Date

November 2 2017

End Date

December 31 2018

Last Update

November 17 2017

Active Locations (1)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 1 (1 locations)

1

The Hong Kong Polytechnic University

Hong Kong, Hong Kong